Cynata Therapeutics Limited (CYP) AI Stock Analysis

• Market Cap: AU$68.86M
• Dividend Yield: N/A
• Average Volume (3M): 233.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: N/A
• EPS Growth: 16.61%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 237,454,380
• 10 Day Avg. Volume: 170,513
• 30 Day Avg. Volume: 233,823
• PEG Ratio: 0.21
• Price to Book (P/B): 5.14
• Price to Sales (P/S): 16.31
• P/FCF Ratio: -3.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.05
• Revenue Forecast (FY): AU$6.40M

• Rating: 56 Neutral
• Price Target: AU$0.30 ▲(3.10% Upside)
• Action: Reiterated Date: 02/13/26
• Date: Action: Reiterated 02/13/26

The score is held back primarily by weak financial performance (large ongoing losses and negative free cash flow despite some stabilization), while technicals provide meaningful support due to a clear uptrend and positive momentum. Valuation is neutral-to-weak because the negative P/E reflects loss-making operations and there is no dividend yield.

Positive Factors

Debt-free balance sheet

Zero reported debt is a durable financial strength: it lowers bankruptcy and interest-service risk, preserves strategic optionality for partnerships or clinical investments, and gives management flexibility to prioritize R&D or licensing without fixed leverage costs over the next several quarters.

Very high gross margins

Near-100% gross margins reflect a structural advantage if therapies scale: low incremental COGS for biologics/licensing can convert revenue into high operating leverage. If Cynata secures partners or commercial uptake, margins support sustainable profitability and attractive royalty economics.

Cymerus allogeneic platform & partnering model

An off-the-shelf allogeneic MSC platform and an explicit partnering/licensing monetization strategy are durable business strengths: scalable manufacturing, simpler logistics than autologous approaches, and potential non-dilutive milestone/royalty income from collaborators reduce execution risk versus sole self-commercialization.

Negative Factors

Sustained negative cash flow

Persistent negative operating and free cash flows indicate ongoing funding dependence. Over a multi-quarter horizon this raises dilution risk from equity raises or the need for partner financing, constraining the firm’s ability to independently advance trials or scale manufacturing without external capital.

Large operating and net losses

Very wide negative margins show the company is not close to break-even absent meaningful revenue or partner deals. Structural cost-to-revenue imbalance limits reinvestment capacity, weakens earnings power, and means sustained losses could continue to pressure capital resources for many quarters.

Declining equity and negative ROE

Material declines in equity and assets alongside persistent negative ROE indicate capital erosion from cumulative losses. This reduces long-term financial flexibility, makes future fundraising more dilutive, and signals shareholder capital has yet to yield positive returns, a structural concern for viability.

Cynata Therapeutics Limited Business Overview & Revenue Model

Company Description

Cynata Therapeutics Limited (CYP) is an Australian biotechnology company focused on the development and commercialization of innovative stem cell therapies. The company specializes in Cymerus™, a proprietary technology for manufacturing mesenchymal stem cells (MSCs) at scale. This platform enables the production of therapeutic stem cells without the limitation of donor availability, supporting the treatment of various diseases and medical conditions. Cynata's core products target applications in regenerative medicine, encompassing indications such as cardiovascular disease, respiratory ailments, and graft-versus-host disease (GvHD).

How the Company Makes Money

Cynata Therapeutics primarily seeks to make money by developing its cell-therapy candidates and then monetizing them through (1) partnering/licensing deals with larger pharmaceutical or biotechnology companies and (2) potential future product commercialization if any candidate receives regulatory approval. In a partnering model, revenue can come from upfront payments on signing, milestone payments tied to development/regulatory/commercial achievements, and ongoing royalties on partner sales; however, specific partnership terms and amounts are null. If Cynata commercializes a therapy itself, revenue would come from selling approved cell-therapy products to hospitals/health systems (or via distributors) and potentially from reimbursement-driven sales in target markets; current commercial product revenue is null. Like many clinical-stage biotechs, the company may also generate non-operating funding through capital raises (equity issuance) and may receive grants or research support; details of such funding as recurring revenue are null.

Cynata Therapeutics Limited Financial Statement Overview

Summary

Financials reflect an early-stage, loss-making profile: volatile revenue with modest recent growth, near-100% gross margin but a cost base far above revenue, and persistently large operating/net losses. Cash flow remains negative (ongoing cash burn) despite some improvement vs. 2023, while the debt-free balance sheet reduces leverage risk but equity/assets have declined alongside negative ROE.

Income Statement

Revenue has been volatile (down sharply from 2022 levels and still well below prior peaks), despite returning to modest growth in 2024 and 2025. Gross margin is strong (near 100% in recent years), but the cost base remains far above revenue, resulting in consistently large operating losses and deeply negative net margins (roughly -420% to -860% across 2023–2025). The trajectory shows some improvement versus the extreme 2023 loss level, but profitability remains a clear weakness.

Balance Sheet

The balance sheet is conservatively levered with zero debt across all periods, which reduces financial risk. However, equity and total assets have declined materially from 2021–2022 to 2025, consistent with ongoing losses and cash burn. Returns on equity are significantly negative each year, highlighting that shareholder capital is not currently generating profits, even though the company is not burdened by leverage.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are negative every year, indicating sustained cash burn to fund operations. While free cash flow outflow improved versus 2023 (less negative in 2024 and 2025) and 2025 shows positive free cash flow growth, the business still relies on external funding to support ongoing losses. Cash flow quality relative to earnings is not a key positive here because both cash flow and net income are negative.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	1.89M	2.32M	1.65M	7.77M	1.55M
Gross Profit	1.89M	2.32M	1.37M	7.49M	1.27M
EBITDA	-9.33M	-9.95M	-15.65M	-6.00M	-8.80M
Net Income	-9.39M	-9.74M	-14.28M	-5.45M	-7.69M
Balance Sheet
Total Assets	7.20M	8.39M	18.99M	26.55M	29.97M
Cash, Cash Equivalents and Short-Term Investments	5.05M	6.21M	16.17M	23.80M	26.72M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.22M	1.17M	2.26M	2.59M	1.60M
Stockholders Equity	5.98M	7.22M	16.73M	23.96M	28.37M
Cash Flow
Free Cash Flow	-8.77M	-9.96M	-14.28M	-3.30M	-5.16M
Operating Cash Flow	-8.72M	-9.96M	-14.28M	-3.30M	-5.16M
Investing Cash Flow	-50.00K	0.00	0.00	0.00	0.00
Financing Cash Flow	7.61M	0.00	6.72M	210.12K	18.20M

Cynata Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYP, the sentiment is Negative. The current price of 0.29 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.34, and above the 200-day MA of 0.25, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 37.20 is Neutral, neither overbought nor oversold. The STOCH value of 18.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CYP.

Cynata Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CYP	56 Neutral	AU$68.86M	-7.57	-179.37%	―	―	16.61%
AVE	53 Neutral	AU$33.06M	-6.66	-258.19%	―	306.88%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPL	50 Neutral	AU$197.36M	27.58	-15.96%	―	-40.74%	-21.21%
NOX	43 Neutral	AU$18.43M	-3.69	2509.60%	―	―	-36.89%
PTX	42 Neutral	AU$58.88M	-5.28	-62.49%	―	―	10.78%
ADO	40 Underperform	AU$32.70M	-10.60	-142.30%	―	110.44%	35.90%

Cynata Therapeutics Limited Corporate Events

Cynata Narrows Half-Year Loss but Faces Going Concern Uncertainty

Cynata Therapeutics reported revenue and other income of $1.77 million for the half-year to 31 December 2025, down about 10% from the prior corresponding period, while its loss after tax narrowed by 27% to $2.66 million. Despite an auditor’s review highlighting a material uncertainty over the group’s ability to continue as a going concern and a significant fall in net tangible asset backing per share, the accounts have been prepared on a going concern basis and no dividend was declared for the period.

The company’s net tangible asset backing per ordinary share dropped sharply to 0.70 cents from 4.21 cents a year earlier, underscoring pressure on its balance sheet. The board’s decision not to pay or recommend a dividend, combined with the going concern warning, indicates continued emphasis on conserving cash and funding ongoing development activities rather than returning capital to shareholders.

The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.41 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.

Cynata to Host Investor Webinar and Expand Online Engagement With Shareholders

Cynata Therapeutics has scheduled an investor webinar for 11:30am AEDT on 4 February 2026, to be hosted by CEO and Managing Director Dr Kilian Kelly, providing an opportunity for shareholders and the broader investment community to receive an update on the company’s activities and key projects. The company is also emphasizing use of its InvestorHub portal, where the webinar recording and other regularly updated materials such as videos, project news and corporate updates will be made available, reflecting a broader push to deepen engagement with current and prospective investors and partners as it advances its clinical-stage cell therapy pipeline.

The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.34 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.

Cynata Nears Key Data Readouts as Pivotal Cell Therapy Trials Advance

Cynata Therapeutics reported strong clinical and operational progress in the December 2025 quarter, highlighted by completion of final patient visits in its large Phase 3 SCUlpTOR osteoarthritis trial of CYP-004 and completion of patient enrolment in its Phase 2 trial of CYP-001 for newly diagnosed high-risk acute graft versus host disease, with efficacy results from both studies expected in the second quarter of 2026. The company also advanced its Phase 1/2 NEREID kidney transplantation study, where an independent safety board cleared the first cohort treated with CYP-001 with no rejection episodes or safety issues, allowing progression to a second cohort with higher dosing; combined with an estimated available cash position of about $3.8 million and a runway into mid-2026, ongoing regulatory engagement and partnering discussions position Cynata for multiple near-term clinical and strategic catalysts that could influence future approval pathways and commercialisation prospects for its Cymerus™ platform.

The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.30 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.

Cynata Raises $1.2m via At-The-Market Facility to Support Cell Therapy Pipeline

Cynata Therapeutics has raised approximately $1.2 million in net proceeds via its At-The-Market Subscription Agreement with Acuity Capital, achieved through the set-off of 4.3 million previously issued shares at a deemed price of $0.28, an 11.1% discount to the last traded price. The funds will be used for working capital, strengthening Cynata’s financial position as it advances multiple Cymerus™-based cell therapy clinical programs and supports ongoing development in a competitive regenerative medicine sector.

The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.30 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.